Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715660 | 0.84 | CA2 (0.53) | SMN1; SMN2RAB9ANPC1HPGDMEN1 | |
| SCHEMBL27405353 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9AKDM4ENPC1GAA | |
| SCHEMBL27996731 | 0.79 | SMN1; SMN2 (0.73) | SMN1; SMN2RAB9AKDM4ENPC1GAA | |
| SCHEMBL8577101 | 0.79 | CA2 (0.49) | SMN1; SMN2RAB9ANPC1HPGDMEN1 | |
| SCHEMBL15267942 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9AKDM4ENPC1GAA | |
| SCHEMBL13484481 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9AKDM4ENPC1GAA | |
| SCHEMBL3040275 | 0.76 | RAB9A (0.59) | SMN1; SMN2RAB9ANPC1GAAMEN1 | |
| SCHEMBL140989 | 0.75 | — | — | |
| SCHEMBL8702006 | 0.74 | CES2 (0.62) | SMN1; SMN2RAB9ANPC1GAAHPGD | |
| SCHEMBL6771010 | 0.74 | HPGD (0.65) | SMN1; SMN2RAB9AKDM4ENPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ITEOS BELGIUM S A (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11427594-B2 | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers | iTeos Belgium SA (BE) | 2022-08-30 | — | — | US | disclosed |
| US-20200102319-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102319-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | SMN1; SMN2 1727/4885RAB9A 1838/4885KDM4E 2990/4885 |
| US-11427594-B2 | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers | ADORA2A, ADORA2B, ADORA1 | SMN1; SMN2 1727/4885RAB9A 1838/4885KDM4E 2990/4885 |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | SMN1; SMN2 1727/4885RAB9A 1838/4885KDM4E 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.